Guardant Health, Inc. (GH) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
N/A
—
5yr avg: 26.99
30Y Low6.1·High46.2
ROE
↓
N/A
—
5yr avg: -1312.2%
30Y Low-438%·High-11%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GH Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Guardant Health, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $17.5B | $12.8B | $3.7B | $3.0B | $2.8B | $10.1B | $12.6B | $7.1B | $3.2B | — | — |
| Enterprise Value | $18.8B | $14.1B | $4.6B | $3.2B | $4.0B | $11.0B | $12.6B | $7.0B | $3.1B | — | — |
| P/E Ratio → | -39.69 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 17.79 | 13.04 | 5.07 | 5.37 | 6.18 | 27.12 | 43.83 | 33.02 | 35.26 | — | — |
| P/B Ratio | — | — | — | 19.09 | 46.18 | 15.71 | 9.27 | 8.35 | 6.09 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
GH EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 14.37 | 6.17 | 5.76 | 8.91 | 29.48 | 43.90 | 32.54 | 33.71 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
GH Profitability
Margins and return-on-capital ratios measuring operating efficiency
Guardant Health, Inc. earns an operating margin of -44.4%. Operating margins have expanded from -100.1% to -44.4% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.5% | 64.5% | 60.8% | 59.7% | 65.2% | 67.1% | 67.7% | 67.0% | 52.3% | 36.6% | 12.4% |
| Operating Margin | -44.4% | -44.4% | -60.0% | -100.1% | -121.1% | -110.0% | -88.9% | -38.4% | -102.5% | -153.7% | -173.7% |
| Net Profit Margin | -42.4% | -42.4% | -59.0% | -85.0% | -145.6% | -108.6% | -88.5% | -35.3% | -93.8% | -167.0% | -182.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -4584.5% | -438.1% | -185.7% | -40.6% | -23.0% | -11.0% | -20.4% | -42.9% | -57.9% |
| ROA | -23.8% | -23.8% | -26.7% | -28.2% | -34.3% | -18.1% | -15.7% | -9.8% | -18.3% | -36.2% | -39.6% |
| ROIC | -34.9% | -34.9% | -63.4% | -50.8% | -29.0% | -21.2% | -18.0% | -10.9% | -22.4% | -38.3% | -52.1% |
| ROCE | -29.4% | -29.4% | -31.2% | -37.7% | -31.8% | -19.5% | -16.5% | -11.5% | -21.5% | -36.0% | -42.9% |
GH Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $1.3B ($1.7B total debt minus $378M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 8.53 | 22.75 | 2.13 | 0.63 | 0.05 | — | 0.00 | 0.21 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | 1.39 | 20.40 | 1.37 | 0.02 | -0.12 | -0.27 | -0.23 | -0.21 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -106.14 | -106.14 | -167.57 | -184.71 | -252.57 | -148.19 | -50.60 | -58.04 | -66.33 | -29.80 | -14.29 |
GH Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Guardant Health, Inc.'s current ratio of 4.84x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 6.54x to 4.84x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.84 | 4.84 | 4.68 | 6.54 | 6.17 | 5.72 | 28.27 | 8.21 | 9.99 | 12.38 | 7.22 |
| Quick Ratio | 4.56 | 4.56 | 4.36 | 6.24 | 5.90 | 5.57 | 27.93 | 8.00 | 9.80 | 12.01 | 7.03 |
| Cash Ratio | 3.97 | 3.97 | 3.72 | 5.68 | 5.23 | 4.79 | 26.87 | 7.19 | 8.92 | 11.28 | 6.67 |
| Asset Turnover | — | 0.49 | 0.50 | 0.32 | 0.28 | 0.17 | 0.13 | 0.22 | 0.15 | 0.15 | 0.22 |
| Inventory Turnover | 4.06 | 4.06 | 4.08 | 3.67 | 3.03 | 4.01 | 4.07 | 4.66 | 4.73 | 4.34 | 7.99 |
| Days Sales Outstanding | — | 51.24 | 54.45 | 57.46 | 78.97 | 95.39 | 67.85 | 81.70 | 143.72 | 93.64 | 50.52 |
GH Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Guardant Health, Inc. returns 0.1% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $125M | $123M | $112M | $102M | $101M | $98M | $91M | $85M | $71M | $13M |
Peer Comparison
Compare GH with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GHYou | $17B | -39.7 | — | — | 64.5% | -44.4% | — | -34.9% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 ILMN | $25B | 29.7 | 22.7 | 26.4 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 NTRA | $33B | -152.2 | — | 303.7 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 FDMT | $505M | -4.0 | — | — | 91.1% | -187.2% | -27.6% | -28.1% | — |
 CGEN | $190M | 5.3 | 3.2 | 6.1 | 87.3% | 43.1% | 44.8% | 85.9% | 0.1 |
 PACB | $435M | -0.8 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
 CDNA | $1B | -65.5 | — | 37.4 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 BNGO | $4M | -0.2 | — | — | 22.0% | -116.9% | -66.2% | -49.1% | — |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $125B | 35.2 | 18.4 | 23.8 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into GH consensus models and risk factors.
View Analysis
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
GH — Frequently Asked Questions
Quick answers to the most common questions about buying GH stock.
What is Guardant Health, Inc.'s P/E ratio?
Guardant Health, Inc.'s current P/E ratio is -39.7x. This places it at the 50th percentile of its historical range.
Is GH stock overvalued?
Based on historical data, Guardant Health, Inc. is trading at a P/E of -39.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Guardant Health, Inc.'s profit margins?
Guardant Health, Inc. has 64.5% gross margin and -44.4% operating margin.